Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

MBCProject_4647_T0_RNA

· B

13208bbb-93cf-5bad-8262-94c9df91f2e6

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
B
subtype
B

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.580
  • INTERFERON_GAMMA_RESPONSE+0.280
  • ESTROGEN_RESPONSE_EARLY+0.190
  • MYC_TARGETS_V2+0.160
  • DNA_REPAIR+0.090
  • E2F_TARGETS+0.050
  • G2M_CHECKPOINT+0.020
  • KRAS_SIGNALING_DN-0.010
  • MITOTIC_SPINDLE-0.010
  • ALLOGRAFT_REJECTION-0.020

Top 10 suppressed

  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.530
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
  • COAGULATION-0.450
  • OXIDATIVE_PHOSPHORYLATION-0.440
  • ANGIOGENESIS-0.420
  • FATTY_ACID_METABOLISM-0.420
  • KRAS_SIGNALING_UP-0.400
  • MYC_TARGETS_V1-0.390
  • PROTEIN_SECRETION-0.390
  • CHOLESTEROL_HOMEOSTASIS-0.380

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120040121.LumB
breast-umap@18
D0.854
2TCGA-60-2721-01A-01R-0851-07
lung-landscapes@6
cohortSQ10.844
3SRR33532821
breast-umap@18
D0.843
4AUR-AF9A-TTP1-A-1-0-R-A741-41
breast-umap@18
D0.840
5SRR1313108
breast-umap@18
B0.839
6SRR33532764
breast-umap@18
D0.824
7SRR35579810
breast-umap@18
B0.823
8SRR8613722
breast-umap@18
E0.819
9SRR6013553
lung-landscapes@6
cohortA30.810
10SRR35579841
breast-umap@18
B0.806

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 7 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.580Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.280Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.190Inavolisib— uncovered
MYC_TARGETS_V20.160Idelalisib— uncovered
DNA_REPAIR0.090Idelalisib— uncovered
E2F_TARGETS0.050Inavolisib— uncovered
G2M_CHECKPOINT0.020Inavolisib— uncovered